{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:17:18Z","timestamp":1783138638355,"version":"3.54.6"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.2169\/internalmedicine.6361-25","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:06:18Z","timestamp":1763589978000},"page":"1825-1828","source":"Crossref","is-referenced-by-count":1,"title":["Hereditary Neuropathy with Liability to Pressure Palsies Unmasked by Polatuzumab Vedotin-containing Chemotherapy"],"prefix":"10.2169","volume":"65","author":[{"given":"Takeru","family":"Kawanami","sequence":"first","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Hirahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Shichijo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Suzuyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gouider R, LeGuern E, Gugenheim M, et al. Clinical, electrophysiologic, and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletion. Neurology 45: 2018-2023, 1995.","DOI":"10.1212\/WNL.45.11.2018"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pareyson D, Scaioli V, Taroni F, et al. Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. Neurology 46: 1133-1137, 1996.","DOI":"10.1212\/WNL.46.4.1133"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Koike H, Hirayama M, Yamamoto M, et al. Age associated axonal features in HNPP with 17p11.2 deletion in Japan. J Neurol Neurosurg Psychiatry 76: 1109-1114, 2005.","DOI":"10.1136\/jnnp.2004.048140"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Attarian S, Fatehi F, Rajabally YA, Pareyson D. Hereditary neuropathy with liability to pressure palsies. J Neurol 267: 2198-2206, 2020.","DOI":"10.1007\/s00415-019-09319-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Koike H, Furukawa S, Mouri N, Fukami Y, Iijima M, Katsuno M. Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies. Neuromuscul Disord 32: 503-511, 2022.","DOI":"10.1016\/j.nmd.2022.04.002"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 77: 1356-1362, 1996.","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1356::AID-CNCR20>3.3.CO;2-S"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hildebrandt G, Holler E, Woenkhaus M, et al. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 11: 743-747, 2000.","DOI":"10.1023\/A:1008369315240"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cavaletti G, Forsey K, Alberti P. Toxic medications in Charcot-Marie-Tooth patients: a systematic review. J Peripher Nerv Syst 28: 295-307, 2023.","DOI":"10.1111\/jns.12566"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Li D, Lee D, Dere RC, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol 176: 3805-3818, 2019.","DOI":"10.1111\/bph.14784"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102: 1458-1465, 2003.","DOI":"10.1182\/blood-2003-01-0039"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Park SB, Cetinkaya-Fisgin A, Argyriou AA, H\u00f6ke A, Cavaletti G, Alberti P. Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence. J Neurol Neurosurg Psychiatry 94: 962-972, 2023.","DOI":"10.1136\/jnnp-2021-328323"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chan SY, Worth R, Ochs S. Block of axoplasmic transport <i>in vitro<\/i> by vinca alkaloids. J Neurobiol 11: 251-264, 1980.","DOI":"10.1002\/neu.480110304"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81: 772-781, 2017.","DOI":"10.1002\/ana.24951"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386: 351-363, 2022.","DOI":"10.1056\/NEJMoa2115304"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Li T, Trinh T, Bosco A, Kiernan MC, Goldstein D, Park SB. Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Support Care Cancer 32: 278, 2024.","DOI":"10.1007\/s00520-024-08484-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kalfakis N, Panas M, Karadima G, Floroskufi P, Kokolakis N, Vassilopoulos D. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 59: 1470-1471, 2002.","DOI":"10.1212\/01.WNL.0000032505.45389.94"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ajitsaria R, Reilly M, Anderson J. Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X. Pediatr Blood Cancer 50: 874-876, 2008.","DOI":"10.1002\/pbc.21221"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer 52: 298-300, 2009.","DOI":"10.1002\/pbc.21786"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nakamura T, Hashiguchi A, Suzuki S, Uozumi K, Tokunaga S, Takashima H. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel <i>EGR2<\/i> mutation. Neurogenetics 13: 77-82, 2012.","DOI":"10.1007\/s10048-012-0313-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38: 3325-3348, 2020.","DOI":"10.1200\/JCO.20.01399"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/13\/65_6361-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:31:41Z","timestamp":1783135901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/13\/65_6361-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":20,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6361-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"6361-25"}}